Data from recent first-line trials strengthened the idea that anti-EGFR targeted agents could positively affect natural history of metastatic colorectal cancer but only when the appropriate clinical and molecular selection is applied [1-6]. Here, EGFR is linked to metastatic colorectal cancer.